<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863912</url>
  </required_header>
  <id_info>
    <org_study_id>1908/2017</org_study_id>
    <nct_id>NCT03863912</nct_id>
  </id_info>
  <brief_title>Impact of Disney Movies During Chemotherapy on QOL of Gynecologic Oncology Patients</brief_title>
  <official_title>Impact of Disney Movies During Chemotherapy on QOL of Gynecologic Oncology Patients: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the impact of Disney movies on quality of life (QOL) of gynecologic oncology
      patients.

      25 Patients are watching Disney movies on portable DVD players during chemotherapy, 25
      patients are not allowed to watch TV.

      EORTC QLQ-C30 and EORTC QLQ-FA12 surveys are given to the patients before and after the six
      chemotherapies.

      Hypothesis: Disney movies can elevate patients QOL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">November 29, 2018</completion_date>
  <primary_completion_date type="Actual">November 29, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Quality of life during 6 cycles of chemotherapy</measure>
    <time_frame>Measured before and after each chemotherapy (at baseline and on average after 3, 6, 9, 12, 15 weeks after inclusion in patients with carboplatin/paclitaxel or after 4, 8, 12, 16, 20 weeks after inclusion in patients with carboplatin/doxorubicin)</time_frame>
    <description>To compare change in Quality of Life, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30 (Version 3)) during 6 cycles of chemotherapy.
The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 (&quot;Not at all&quot;), 2 (&quot;A little&quot;), 3 (&quot;Quite a bit&quot;) and 4 (&quot;Very much&quot;). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.
The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 (&quot;very poor&quot;) to 7 (&quot;excellent&quot;). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Fatigue during 6 cycles of chemotherapy</measure>
    <time_frame>Measured before and after each chemotherapy (at baseline and on average after 3, 6, 9, 12, 15 weeks after inclusion in patients with carboplatin/paclitaxel or after 4, 8, 12, 16, 20 weeks after inclusion in patients with carboplatin/doxorubicin)</time_frame>
    <description>To compare change in Fatigue, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Fatigue (EORTC QLQ-FA12) during 6 cycles of chemotherapy.
The EORTC QLQ-FA12 uses for the questions 1 to 12 a four-point scale. The scale scores from 1 to 4: 1 (&quot;Not at all&quot;), 2 (&quot;A little&quot;), 3 (&quot;Quite a bit&quot;) and 4 (&quot;Very much&quot;). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. Raw score has to be calculated using the mean value for the questions 1 to 12.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Chemotherapy</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Disney</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>watch Disney movies and fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Disney movie</intervention_name>
    <description>Disney movie on portable DVD Player.</description>
    <arm_group_label>Disney</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC QLQ-C30 and EORTC QLQ-FA12 surveys</intervention_name>
    <description>EORTC QLQ-C30 and EORTC QLQ-FA12 surveys</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Disney</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  planned 6 cycles of chemotherapy with carboplatin/paclitaxel or carboplatin/pegylated
             liposomal doxorubicin

          -  Age &gt;18 years

        Exclusion Criteria:

          -  inadequate knowledge of the German language
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only gynecological cancer patients are included</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Pils, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of General Gynecology and Gynecologic Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>May 1, 2019</last_update_submitted>
  <last_update_submitted_qc>May 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Sophie Pils</investigator_full_name>
    <investigator_title>MD, Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

